Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 36,600 shares, a growth of 10.2% from the August 31st total of 33,200 shares. Based on an average daily trading volume, of 8,900 shares, the short-interest ratio is presently 4.1 days. Currently, 1.3% of the company’s shares are short sold.
Eterna Therapeutics Trading Down 7.0 %
ERNA stock traded down $0.07 during trading on Tuesday, reaching $0.98. 17,647 shares of the stock were exchanged, compared to its average volume of 13,617. The firm has a market capitalization of $5.28 million, a price-to-earnings ratio of -0.25 and a beta of 4.43. The company has a current ratio of 0.37, a quick ratio of 0.37 and a debt-to-equity ratio of 3.03. The business has a 50 day moving average price of $1.64 and a 200-day moving average price of $1.89. Eterna Therapeutics has a 1 year low of $0.84 and a 1 year high of $2.63.
Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($1.02) earnings per share (EPS) for the quarter. The company had revenue of $0.05 million during the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%.
Institutional Inflows and Outflows
Eterna Therapeutics Company Profile
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
See Also
- Five stocks we like better than Eterna Therapeutics
- What is Forex and How Does it Work?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What is the Euro STOXX 50 Index?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.